Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook

Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-ch...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Therapeutic advances in neurological disorders Ročník 18; s. 17562864251372752
Hlavní autoři: Klotz, Luisa, Berger, Thomas, Brownlee, Wallace J., Chan, Andrew, Lycke, Jan, Oreja-Guevara, Celia, Palavra, Filipe, Sacca, Francesco, Sejbaek, Tobias, Weber, Martin S., Giovannoni, Gavin
Médium: Journal Article
Jazyk:angličtina
Vydáno: England SAGE Publishing 01.01.2025
Témata:
multiple sclerosis
natalizumab
Neurosciences
Neurovetenskaper
treatment strategies
treatment strategies
multiple sclerosis
natalizumab
ISSN:1756-2864, 1756-2856, 1756-2864
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-characterized safety profile, provided that the risk of progressive multifocal leukoencephalopathy (PML) is monitored and mitigated. This review explores the long-term clinical impact of natalizumab. It draws on two decades of experience to guide treatment strategies with natalizumab, including its use early in the disease course, switching to natalizumab, its use during vaccination, and PML risk management and exit strategies. Guidance on the use of natalizumab in pregnant and breastfeeding women with MS, children with MS, and people with comorbidities is discussed, along with reflections on what has been learned from 20 years with natalizumab, and what the future holds for this impactful treatment in MS and beyond.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1756-2864
1756-2856
1756-2864
DOI:10.1177/17562864251372752